{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:17:48Z","timestamp":1785410268469,"version":"3.56.0"},"reference-count":85,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), represents\na novel therapeutic agent for diabetes management. Over the past decade, studies have consistently\ndemonstrated that EMPA not only effectively lowers blood glucose levels but also confers substantial\ncardiovascular benefits without inducing hypoglycemia. This holds for individuals with or without\ndiabetes, highlighting EMPA\u2019s potential in mitigating the risk of adverse cardiovascular events\nand cardiovascular mortality. The underlying mechanisms driving these advantageous effects remain\nincompletely understood, with presently elucidated pathways encompassing blood pressure reduction,\noxidative stress attenuation, anti-inflammatory properties, metabolic regulation, uric acid level\nmodulation, inhibition of Na+\/H+ exchangers, preservation of mitochondrial function, vascular protection,\nand regulation of myocardial autophagy. In this review, we considered the effects and mechanisms\nof EMPA in combating diabetic cardiomyopathy (DCM), underscoring its therapeutic relevance\nin addressing cardiovascular complications associated with diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115701611319744250116092707","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T02:16:09Z","timestamp":1738030569000},"page":"301-310","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Roles of Empagliflozin in Diabetic Cardiomyopathy: A Review"],"prefix":"10.2174","volume":"23","author":[{"given":"Hao","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"},{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"},{"name":"Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinglin","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangfeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"},{"name":"Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibin","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6950-7545","authenticated-orcid":true,"given":"Wenyan","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"},{"name":"Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"Jia G.","year":"2018","unstructured":"Jia G.; Hill M.A.; Sowers J.R.; Diabetic cardiomyopathy. Circ Res  2018,122(4),624-638","journal-title":"Circ Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.apsb.2021.08.026","volume":"12","author":"Wei J.","year":"2022","unstructured":"Wei J.; Zhao Y.; Liang H.; Du W.; Wang L.; Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy. Acta Pharm Sin B  2022,12(1),1-17","journal-title":"Acta Pharm Sin B"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","volume":"126","author":"Ritchie R.H.","year":"2020","unstructured":"Ritchie R.H.; Abel E.D.; Basic mechanisms of diabetic heart disease. Circ Res  2020,126(11),1501-1525","journal-title":"Circ Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"Kenny H.C.","year":"2019","unstructured":"Kenny H.C.; Abel E.D.; Heart failure in type 2 diabetes mellitus. Circ Res  2019,124(1),121-141","journal-title":"Circ Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"154838","DOI":"10.1016\/j.metabol.2021.154838","volume":"123","author":"Yun J.S.","year":"2021","unstructured":"Yun J.S.; Ko S.H.; Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism  2021,123,154838","journal-title":"Metabolism"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3","volume":"3","author":"Udell J.A.","year":"2015","unstructured":"Udell J.A.; Cavender M.A.; Bhatt D.L.; Chatterjee S.; Farkouh M.E.; Scirica B.M.; Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: A meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol  2015,3(5),356-366","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","volume":"20","author":"Packer M.","year":"2023","unstructured":"Packer M.; SGLT2 inhibitors: Role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol  2023,20(7),443-462","journal-title":"Nat Rev Cardiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"Li C.","year":"2019","unstructured":"Li C.; Zhang J.; Xue M.; SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol  2019,18(1),15","journal-title":"Cardiovasc Diabetol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s13300-019-00680-5","volume":"10","author":"Nagahisa T.","year":"2019","unstructured":"Nagahisa T.; Saisho Y.; Cardiorenal protection: Potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Ther  2019,10(5),1733-1752","journal-title":"Diabetes Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ejhf.1473","volume":"21","author":"Yurista S.R.","year":"2019","unstructured":"Yurista S.R.; Sillj\u00e9 H.H.W.; Oberdorf-Maass S.U.; Sodium\u2013glucose co\u2010transporter 2 inhibition with empagliflozin improves cardiac function in non\u2010diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail  2019,21(7),862-873","journal-title":"Eur J Heart Fail"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"Zelniker T.A.","year":"2018","unstructured":"Zelniker T.A.; Braunwald E.; Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes. J Am Coll Cardiol  2018,72(15),1845-1855","journal-title":"J Am Coll Cardiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med  2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"Tsapas A.","year":"2020","unstructured":"Tsapas A.; Avgerinos I.; Karagiannis T.; Comparative effectiveness of glucose-lowering drugs for type 2 diabetes. Ann Intern Med  2020,173(4),278-286","journal-title":"Ann Intern Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"142","author":"Griffin M.","year":"2020","unstructured":"Griffin M.; Rao V.S.; Ivey-Miranda J.; Empagliflozin in heart failure. Circulation  2020,142(11),1028-1039","journal-title":"Circulation"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"n1171","DOI":"10.1136\/bmj.n1171","volume":"373","author":"Guo J.","year":"2021","unstructured":"Guo J.; Smith S.M.; Newer drug treatments for type 2 diabetes. BMJ  2021,373(1171),n1171","journal-title":"BMJ"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","volume":"78","author":"Jia G.","year":"2021","unstructured":"Jia G.; Sowers J.R.; Hypertension in diabetes: An update of basic mechanisms and clinical disease. Hypertension  2021,78(5),1197-1205","journal-title":"Hypertension"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","volume":"76","author":"Omar M.","year":"2020","unstructured":"Omar M.; Jensen J.; Frederiksen P.H.; Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol  2020,76(23),2740-2751","journal-title":"J Am Coll Cardiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2337\/db21-0721","volume":"71","author":"Wolsk E.","year":"2022","unstructured":"Wolsk E.; J\u00fcrgens M.; Schou M.; Randomized controlled trial of the hemodynamic effects of empagliflozin in patients with type 2 diabetes at high cardiovascular risk: The SIMPLE trial. Diabetes  2022,71(4),812-820","journal-title":"Diabetes"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"Nassif M.E.","year":"2021","unstructured":"Nassif M.E.; Qintar M.; Windsor S.L.; Empagliflozin effects on pulmonary artery pressure in patients with heart failure. Circulation  2021,143(17),1673-1686","journal-title":"Circulation"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"Cherney D.Z.I.","year":"2014","unstructured":"Cherney D.Z.I.; Perkins B.A.; Soleymanlou N.; Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation  2014,129(5),587-597","journal-title":"Circulation"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"Vallon V.","year":"2014","unstructured":"Vallon V.; Gerasimova M.; Rose M.A.; SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol  2014,306(2),F194-F204","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Lytvyn Y.","year":"2017","unstructured":"Lytvyn Y.; Bjornstad P.; Udell J.A.; Lovshin J.A.; Cherney D.Z.I.; Sodium glucose cotransporter-2 inhibition in heart failure. Circulation  2017,136(17),1643-1658","journal-title":"Circulation"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"Lopaschuk G.D.","year":"2020","unstructured":"Lopaschuk G.D.; Verma S.; Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. JACC Basic Transl Sci  2020,5(6),632-644","journal-title":"JACC Basic Transl Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","volume":"140","author":"Kidokoro K.","year":"2019","unstructured":"Kidokoro K.; Cherney D.Z.I.; Bozovic A.; Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation  2019,140(4),303-315","journal-title":"Circulation"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"Wanner C.","year":"2016","unstructured":"Wanner C.; Inzucchi S.E.; Lachin J.M.; Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med  2016,375(4),323-334","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"Vallon V.","year":"2021","unstructured":"Vallon V.; Verma S.; Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol  2021,83(1),503-528","journal-title":"Annu Rev Physiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","volume":"71","author":"Johnson R.J.","year":"2018","unstructured":"Johnson R.J.; Bakris G.L.; Borghi C.; Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis  2018,71(6),851-865","journal-title":"Am J Kidney Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1210\/clinem\/dgac210","volume":"107","author":"Deng X.","year":"2022","unstructured":"Deng X.; Zhang C.; Wang P.; Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes. J Clin Endocrinol Metab  2022,107(7),1888-1896","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","volume":"98","author":"Hesp A.C.","year":"2020","unstructured":"Hesp A.C.; Schaub J.A.; Prasad P.V.; The role of renal hypoxia in the pathogenesis of diabetic kidney disease: A promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int  2020,98(3),579-589","journal-title":"Kidney Int"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2022.12.088","volume":"195","author":"Lu Q.","year":"2023","unstructured":"Lu Q.; Yang L.; Xiao J.J.; Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway. Free Radic Biol Med  2023,195,89-102","journal-title":"Free Radic Biol Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41569-020-00465-5","volume":"18","author":"Ng A.C.T.","year":"2021","unstructured":"Ng A.C.T.; Delgado V.; Borlaug B.A.; Bax J.J.; Diabesity: The combined burden of obesity and diabetes on heart disease and the role of imaging. Nat Rev Cardiol  2021,18(4),291-304","journal-title":"Nat Rev Cardiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.2337\/dcS15-3006","volume":"39","author":"Fioretto P.","year":"2016","unstructured":"Fioretto P.; Zambon A.; Rossato M.; Busetto L.; Vettor R.; SGLT2 inhibitors and the diabetic kidney. Diabetes Care  2016,39(Suppl. 2),S165-S171","journal-title":"Diabetes Care"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"Soga F.","year":"2018","unstructured":"Soga F.; Tanaka H.; Tatsumi K.; Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol  2018,17(1),132","journal-title":"Cardiovasc Diabetol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/cvr\/cvx012","volume":"113","author":"Nishida K.","year":"2017","unstructured":"Nishida K.; Otsu K.; Inflammation and metabolic cardiomyopathy. Cardiovasc Res  2017,113(4),389-398","journal-title":"Cardiovasc Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","volume":"21","author":"Poznyak A.","year":"2020","unstructured":"Poznyak A.; Grechko A.V.; Poggio P.; Myasoedova V.A.; Alfieri V.; Orekhov A.N.; The diabetes mellitus\u2013atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci  2020,21(5),1835","journal-title":"Int J Mol Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","volume":"15","author":"Kusaka H.","year":"2016","unstructured":"Kusaka H.; Koibuchi N.; Hasegawa Y.; Ogawa H.; Kim-Mitsuyama S.; Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol  2016,15(1),157","journal-title":"Cardiovasc Diabetol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3390\/antiox10081228","volume":"10","author":"Canet F.","year":"2021","unstructured":"Canet F.; Iannantuoni F.; Mara\u00f1on A.M.; Does empagliflozin modulate leukocyte\u2013endothelium interactions, oxidative stress, and inflammation in type 2 diabetes? Antioxidants  2021,10(8),1228","journal-title":"Antioxidants"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"101799","DOI":"10.1016\/j.redox.2020.101799","volume":"37","author":"Kang Q.","year":"2020","unstructured":"Kang Q.; Yang C.; Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol  2020,37,101799","journal-title":"Redox Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.tcm.2014.03.003","volume":"24","author":"Matsushima S.","year":"2014","unstructured":"Matsushima S.; Tsutsui H.; Sadoshima J.; Physiological and pathological functions of NADPH oxidases during myocardial ischemia\u2013reperfusion. Trends Cardiovasc Med  2014,24(5),202-205","journal-title":"Trends Cardiovasc Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/414813a","volume":"414","author":"Brownlee M.","year":"2001","unstructured":"Brownlee M.; Biochemistry and molecular cell biology of diabetic complications. Nature  2001,414(6865),813-820","journal-title":"Nature"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2019.07.009","volume":"5","author":"Sabbah H.N.","year":"2020","unstructured":"Sabbah H.N.; Targeting the mitochondria in heart failure. JACC Basic Transl Sci  2020,5(1),88-106","journal-title":"JACC Basic Transl Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"Kolijn D.","year":"2021","unstructured":"Kolijn D.; Pabel S.; Tian Y.; Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovasc Res  2021,117(2),495-507","journal-title":"Cardiovasc Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","volume":"24","author":"Steinberg G.R.","year":"2023","unstructured":"Steinberg G.R.; Hardie D.G.; New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol  2023,24(4),255-272","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/db19-0991","volume":"69","author":"Sun X.","year":"2020","unstructured":"Sun X.; Han F.; Lu Q.; Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated ampk-mtor signaling and redox homeostasis in high-fat diet\u2013induced obese mice. Diabetes  2020,69(6),1292-1305","journal-title":"Diabetes"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/dmrr.689","volume":"23","author":"Chen S.","year":"2007","unstructured":"Chen S.; Khan Z.A.; Karmazyn M.; Chakrabarti S.; Role of endothelin\u20101, sodium hydrogen exchanger\u20101 and mitogen activated protein kinase (MAPK) activation in glucose\u2010induced cardiomyocyte hypertrophy. Diabetes Metab Res Rev  2007,23(5),356-367","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"Uthman L.","year":"2018","unstructured":"Uthman L.; Baartscheer A.; Bleijlevens B.; Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia  2018,61(3),722-726","journal-title":"Diabetologia"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"Baartscheer A.","year":"2017","unstructured":"Baartscheer A.; Schumacher C.A.; W\u00fcst R.C.I.; Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia  2017,60(3),568-573","journal-title":"Diabetologia"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","volume":"117","author":"Chung Y.J.","year":"2021","unstructured":"Chung Y.J.; Park K.C.; Tokar S.; Off-target effects of sodium-glucose co-transporter 2 blockers: Empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res  2021,117(14),2794-2806","journal-title":"Cardiovasc Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","volume":"128","author":"Lopaschuk G.D.","year":"2021","unstructured":"Lopaschuk G.D.; Karwi Q.G.; Tian R.; Wende A.R.; Abel E.D.; Cardiac energy metabolism in heart failure. Circ Res  2021,128(10),1487-1513","journal-title":"Circ Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/cvr\/cvz045","volume":"115","author":"Ho K.L.","year":"2019","unstructured":"Ho K.L.; Zhang L.; Wagg C.; Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. Cardiovasc Res  2019,115(11),1606-1616","journal-title":"Cardiovasc Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","volume":"3","author":"Verma S.","year":"2018","unstructured":"Verma S.; Rawat S.; Ho K.L.; Empagliflozin increases cardiac energy production in diabetes. JACC Basic Transl Sci  2018,3(5),575-587","journal-title":"JACC Basic Transl Sci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2337\/dc22-0885","volume":"46","author":"Abdelgani S.","year":"2023","unstructured":"Abdelgani S.; Khattab A.; Adams J.; Distinct mechanisms responsible for the increase in glucose production and ketone formation caused by empagliflozin in T2DM patients. Diabetes Care  2023,46(5),978-984","journal-title":"Diabetes Care"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/cvr\/cvy246","volume":"114","author":"Abdurrachim D.","year":"2018","unstructured":"Abdurrachim D.; Manders E.; Nicolay K.; Mayoux E.; Prompers J.J.; Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db\/db mice. Cardiovasc Res  2018,114(14),1843-1844","journal-title":"Cardiovasc Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.2337\/db21-0270","volume":"70","author":"Thirunavukarasu S.","year":"2021","unstructured":"Thirunavukarasu S.; Jex N.; Chowdhary A.; Empagliflozin treatment is associated with improvements in cardiac energetics and function and reductions in myocardial cellular volume in patients with type 2 diabetes. Diabetes  2021,70(12),2810-2822","journal-title":"Diabetes"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJMoa2200436","volume":"387","author":"Nathan D.M.","year":"2022","unstructured":"Nathan D.M.; Lachin J.M.; Bebu I.; Glycemia reduction in type 2 diabetes \u2014 Microvascular and cardiovascular outcomes. N Engl J Med  2022,387(12),1075-1088","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12933-015-0309-x","volume":"14","author":"M\u00e1ty\u00e1s C.","year":"2015","unstructured":"M\u00e1ty\u00e1s C.; N\u00e9meth B.T.; Ol\u00e1h A.; The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol  2015,14(1),145","journal-title":"Cardiovasc Diabetol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1042\/CS20190585","volume":"133","author":"Xue M.","year":"2019","unstructured":"Xue M.; Li T.; Wang Y.; Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clin Sci  2019,133(15),1705-1720","journal-title":"Clin Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"Adingupu D.D.","year":"2019","unstructured":"Adingupu D.D.; G\u00f6pel S.O.; Gr\u00f6nros J.; SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob\u2212\/\u2212 mice. Cardiovasc Diabetol  2019,18(1),16","journal-title":"Cardiovasc Diabetol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","volume":"19","author":"Spigoni V.","year":"2020","unstructured":"Spigoni V.; Fantuzzi F.; Carubbi C.; Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: Potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol  2020,19(1),46","journal-title":"Cardiovasc Diabetol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","volume":"4","author":"Juni R.P.","year":"2019","unstructured":"Juni R.P.; Kuster D.W.D.; Goebel M.; Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin. JACC Basic Transl Sci  2019,4(5),575-591","journal-title":"JACC Basic Transl Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"Steven S.","year":"2017","unstructured":"Steven S.; Oelze M.; Hanf A.; The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol  2017,13,370-385","journal-title":"Redox Biol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1161\/01.RES.87.11.999","volume":"87","author":"Oelze M.","year":"2000","unstructured":"Oelze M.; Mollnau H.; Hoffmann N.; Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide\/cGMP signaling and endothelial dysfunction. Circ Res  2000,87(11),999-1005","journal-title":"Circ Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.redox.2017.01.013","volume":"11","author":"Rovira-Llopis S.","year":"2017","unstructured":"Rovira-Llopis S.; Ba\u00f1uls C.; Diaz-Morales N.; Hernandez-Mijares A.; Rocha M.; Victor V.M.; Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. Redox Biol  2017,11,637-645","journal-title":"Redox Biol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41467-018-08276-6","volume":"10","author":"Ferreira J.C.B.","year":"2019","unstructured":"Ferreira J.C.B.; Campos J.C.; Qvit N.; A selective inhibitor of mitofusin 1-\u03b2IIPKC association improves heart failure outcome in rats. Nat Commun  2019,10(1),329","journal-title":"Nat Commun"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"15927","DOI":"10.1073\/pnas.0407043101","volume":"101","author":"Cipolat S.","year":"2004","unstructured":"Cipolat S.; de Brito O.M.; Dal Zilio B.; Scorrano L.; OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci USA  2004,101(45),15927-15932","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.freeradbiomed.2019.10.008","volume":"145","author":"Ren L.","year":"2019","unstructured":"Ren L.; Han F.; Xuan L.; Clusterin ameliorates endothelial dysfunction in diabetes by suppressing mitochondrial fragmentation. Free Radic Biol Med  2019,145,357-373","journal-title":"Free Radic Biol Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/1122494","volume":"2022","author":"Wang J.","year":"2022","unstructured":"Wang J.; Huang X.; Liu H.; Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function. Oxid Med Cell Longev  2022,2022,1-16","journal-title":"Oxid Med Cell Longev"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"Zhou H.","year":"2018","unstructured":"Zhou H.; Wang S.; Zhu P.; Hu S.; Chen Y.; Ren J.; Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol  2018,15,335-346","journal-title":"Redox Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Shao Q.","year":"2019","unstructured":"Shao Q.; Meng L.; Lee S.; Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol  2019,18(1),165","journal-title":"Cardiovasc Diabetol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00018-022-04595-6","volume":"79","author":"Ashraf R.","year":"2022","unstructured":"Ashraf R.; Kumar S.; Mfn2-mediated mitochondrial fusion promotes autophagy and suppresses ovarian cancer progression by reducing ROS through AMPK\/mTOR\/ERK signaling. Cell Mol Life Sci  2022,79(11),573","journal-title":"Cell Mol Life Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrcardio.2017.35","volume":"14","author":"Delbridge L.M.D.","year":"2017","unstructured":"Delbridge L.M.D.; Mellor K.M.; Taylor D.J.; Gottlieb R.A.; Myocardial stress and autophagy: Mechanisms and potential therapies. Nat Rev Cardiol  2017,14(7),412-425","journal-title":"Nat Rev Cardiol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41401-020-0490-7","volume":"42","author":"Song S.","year":"2021","unstructured":"Song S.; Ding Y.; Dai G.; Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation. Acta Pharmacol Sin  2021,42(2),230-241","journal-title":"Acta Pharmacol Sin"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ncb2883","volume":"16","author":"Cai Z.","year":"2014","unstructured":"Cai Z.; Jitkaew S.; Zhao J.; Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol  2014,16(1),55-65","journal-title":"Nat Cell Biol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-022-01602-9","volume":"21","author":"Cao T.","year":"2022","unstructured":"Cao T.; Ni R.; Ding W.; MLKL-mediated necroptosis is a target for cardiac protection in mouse models of type-1 diabetes. Cardiovasc Diabetol  2022,21(1),165","journal-title":"Cardiovasc Diabetol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/cvr\/cvad009","volume":"119","author":"Madonna R.","year":"2023","unstructured":"Madonna R.; Moscato S.; Cufaro M.C.; Empagliflozin inhibits excessive autophagy through the AMPK\/GSK3\u03b2 signalling pathway in diabetic cardiomyopathy. Cardiovasc Res  2023,119(5),1175-1189","journal-title":"Cardiovasc Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"Anker S.D.","year":"2021","unstructured":"Anker S.D.; Butler J.; Filippatos G.; Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med  2021,385(16),1451-1461","journal-title":"N Engl J Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2213-8587(22)00387-4","volume":"11","author":"Laffel L.M.","year":"2023","unstructured":"Laffel L.M.; Danne T.; Klingensmith G.J.; Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): A multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol  2023,11(3),169-181","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"Lee M.M.Y.","year":"2021","unstructured":"Lee M.M.Y.; Brooksbank K.J.M.; Wetherall K.; Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation  2021,143(6),516-525","journal-title":"Circulation"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","volume":"142","author":"Mordi N.A.","year":"2020","unstructured":"Mordi N.A.; Mordi I.R.; Singh J.S.; McCrimmon R.J.; Struthers A.D.; Lang C.C.; Renal and cardiovascular effects of sglt2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure. Circulation  2020,142(18),1713-1724","journal-title":"Circulation"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","volume":"19","author":"Shimizu W.","year":"2020","unstructured":"Shimizu W.; Kubota Y.; Hoshika Y.; Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: The EMBODY trial. Cardiovasc Diabetol  2020,19(1),148","journal-title":"Cardiovasc Diabetol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jcmg.2020.10.017","volume":"14","author":"Mason T.","year":"2021","unstructured":"Mason T.; Coelho-Filho O.R.; Verma S.; Empagliflozin reduces myocardial extracellular volume in patients with type 2 diabetes and coronary artery disease. JACC Cardiovasc Imaging  2021,14(6),1164-1173","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","volume":"20","author":"Gaborit B.","year":"2021","unstructured":"Gaborit B.; Ancel P.; Abdullah A.E.; Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: The EMPACEF study. Cardiovasc Diabetol  2021,20(1),57","journal-title":"Cardiovasc Diabetol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-020-01175-5","volume":"20","author":"Rau M.","year":"2021","unstructured":"Rau M.; Thiele K.; Hartmann N.U.K.; Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: A randomized controlled study. Cardiovasc Diabetol  2021,20(1),6","journal-title":"Cardiovasc Diabetol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/dom.14933","volume":"25","author":"Brandt-Jacobsen N.H.","year":"2023","unstructured":"Brandt-Jacobsen N.H.; J\u00fcrgens M.; Hasbak P.; Reduction of cardiac adipose tissue volume with short\u2010term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial. Diabetes Obes Metab  2023,25(3),844-855","journal-title":"Diabetes Obes Metab"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12933-023-01849-w","volume":"22","author":"Puar P.","year":"2023","unstructured":"Puar P.; Hibino M.; Mazer C.D.; Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin. Cardiovasc Diabetol  2023,22(1),152","journal-title":"Cardiovasc Diabetol"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611319744250116092707","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238881\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611319744250116092707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T07:16:53Z","timestamp":1762759013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238881\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115701611319744250116092707","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}